Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from ...

DRESHER, PA. (WPVI) -- We need bacteria to digest food and absorb nutrients. However, when a bacteria commonly found in soil and water gets into our lungs, it can cause trouble, in the form of a MAC ...

AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of patients reported improvements to quality of life compared with placebo. Nontuberculous ...

Everyone breathes in Mycobacterium avium complex (MAC) bacteria from time to time, but most people don't get sick. These bacteria, cousins of the deadly Mycobacterium tuberculosis, tend to live out ...

Shares of Insmed INSM gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025.

Avian tuberculosis, also known as mycobacterium avium complex (MAC) or MAC lung disease, is a respiratory illness. It can lead to symptoms such as chronic cough, shortness of breath, and weight loss.

Accurate detection is essential to prevent misdiagnosis and ensure the right treatment, particularly in cases involving drug-resistant TB or NTM infections. The Hi-PCR ® MTB/NTM Probe PCR Kit offers a ...